Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.
Applied Therapeutics, Inc. (APLT) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare metabolic disorders and diabetic complications. This page serves as the definitive source for official news and developments related to their innovative aldose reductase inhibitor (ARI) pipeline.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes press releases detailing phase updates for govorestat (Galactosemia/SORD Deficiency), AT-001 (diabetic cardiomyopathy), and AT-003 (diabetic retinopathy), along with partnership announcements and research publications.
All content is rigorously verified to ensure accuracy and relevance, providing a trustworthy resource for tracking APLT's progress in addressing high unmet medical needs. Bookmark this page for streamlined access to critical updates about their CNS-penetrant therapies and regulatory engagements.
Applied Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive securities purchase agreement for the private placement of 9,735,731 shares of common stock at $0.946 each and 22,000,000 pre-funded warrants at $0.945, with gross proceeds expected to total approximately $30 million. This transaction is led by Venrock Healthcare Capital Partners and is set to close around April 26, 2023. The funds will be allocated to research and development, pipeline candidate registration, and general corporate purposes, extending the company's operational runway through mid-2024. The securities are not registered under the Securities Act and will require a registration statement for resale.
Applied Therapeutics (Nasdaq: APLT) announced positive results from the ACTION-Galactosemia Kids trial for govorestat, a treatment for Galactosemia. The trial demonstrated long-term clinical benefits in improving daily activities, behavior, cognition, and motor skills compared to placebo. Although not statistically significant on the primary endpoint, systematic improvements were observed. The company plans to request a pre-NDA meeting with the FDA and submit a Marketing Authorization Application with the EMA in mid-2023. Approximately 3,000 patients in the US and 4,000 in the EU suffer from Galactosemia, indicating a significant market need.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
